Detection of pancreatic cancer cells (SUIT-2) using an FET-based biosensor with an extended au gate

Byunghyun Cho, Hee Ho Lee, Jang Kyoo Shin, Masaharu Murata, Kenoki Ouchida, Makoto Hashizume

Research output: Contribution to journalArticle

Abstract

In this paper, we assess the feasibility of detecting human pancreatic cancer cells using a field effect transistor (FET)-based biosensor with an extended Au gate for medical application. Pancreatic cancer is one of the most fatal cancers, and is very difficult to diagnose in its early stages. Gemcitabine is an anticancer drug, and when used in chemotherapy it induces cell death. During apoptosis, the surface potential of the pancreatic cancer cells is changed by gemcitabine. In the present study, this change was detected using an FET-based biosensor. This biosensor was fabricated with an extended Au gate, whose surface is a sensing area for cancer cells. A null-balancing circuit was used in the measurement system, and the LabVIEW software platform allowed the immune-reaction at the Au gate to be detected as an output voltage. The cancer cells were incubated for one day; during this time, the cancer cells adhered to the Au extended gate surface. As gemcitabine was introduced to the cancer cells in vitro, changes in the output of the biosensor were monitored. Pancreatic cancer cells with a resistance to gemcitabine were used to verify that the change in the output of the biosensor was due only to the interaction between the cancer cells and the gemcitabine. We also investigated the relationship between the starting time of the reaction and the concentration of the anticancer drug.

Original languageEnglish
Pages (from-to)131-137
Number of pages7
JournalBiomedical Engineering - Applications, Basis and Communications
Volume24
Issue number2
DOIs
Publication statusPublished - Apr 1 2012

Fingerprint

gemcitabine
Biosensing Techniques
Field effect transistors
Pancreatic Neoplasms
Biosensors
Cells
Neoplasms
Cell death
Antigen-antibody reactions
Chemotherapy
Surface potential
Medical applications
Pharmaceutical Preparations
Cell Death
Software
Apoptosis
Drug Therapy
Networks (circuits)
Electric potential

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Bioengineering
  • Biomedical Engineering

Cite this

Detection of pancreatic cancer cells (SUIT-2) using an FET-based biosensor with an extended au gate. / Cho, Byunghyun; Lee, Hee Ho; Shin, Jang Kyoo; Murata, Masaharu; Ouchida, Kenoki; Hashizume, Makoto.

In: Biomedical Engineering - Applications, Basis and Communications, Vol. 24, No. 2, 01.04.2012, p. 131-137.

Research output: Contribution to journalArticle

Cho, Byunghyun ; Lee, Hee Ho ; Shin, Jang Kyoo ; Murata, Masaharu ; Ouchida, Kenoki ; Hashizume, Makoto. / Detection of pancreatic cancer cells (SUIT-2) using an FET-based biosensor with an extended au gate. In: Biomedical Engineering - Applications, Basis and Communications. 2012 ; Vol. 24, No. 2. pp. 131-137.
@article{9f87ada0b60148a2b2d67e2ff08bf589,
title = "Detection of pancreatic cancer cells (SUIT-2) using an FET-based biosensor with an extended au gate",
abstract = "In this paper, we assess the feasibility of detecting human pancreatic cancer cells using a field effect transistor (FET)-based biosensor with an extended Au gate for medical application. Pancreatic cancer is one of the most fatal cancers, and is very difficult to diagnose in its early stages. Gemcitabine is an anticancer drug, and when used in chemotherapy it induces cell death. During apoptosis, the surface potential of the pancreatic cancer cells is changed by gemcitabine. In the present study, this change was detected using an FET-based biosensor. This biosensor was fabricated with an extended Au gate, whose surface is a sensing area for cancer cells. A null-balancing circuit was used in the measurement system, and the LabVIEW software platform allowed the immune-reaction at the Au gate to be detected as an output voltage. The cancer cells were incubated for one day; during this time, the cancer cells adhered to the Au extended gate surface. As gemcitabine was introduced to the cancer cells in vitro, changes in the output of the biosensor were monitored. Pancreatic cancer cells with a resistance to gemcitabine were used to verify that the change in the output of the biosensor was due only to the interaction between the cancer cells and the gemcitabine. We also investigated the relationship between the starting time of the reaction and the concentration of the anticancer drug.",
author = "Byunghyun Cho and Lee, {Hee Ho} and Shin, {Jang Kyoo} and Masaharu Murata and Kenoki Ouchida and Makoto Hashizume",
year = "2012",
month = "4",
day = "1",
doi = "10.4015/S1016237212500196",
language = "English",
volume = "24",
pages = "131--137",
journal = "Biomedical Engineering - Applications, Basis and Communications",
issn = "1016-2372",
publisher = "World Scientific Publishing Co. Pte Ltd",
number = "2",

}

TY - JOUR

T1 - Detection of pancreatic cancer cells (SUIT-2) using an FET-based biosensor with an extended au gate

AU - Cho, Byunghyun

AU - Lee, Hee Ho

AU - Shin, Jang Kyoo

AU - Murata, Masaharu

AU - Ouchida, Kenoki

AU - Hashizume, Makoto

PY - 2012/4/1

Y1 - 2012/4/1

N2 - In this paper, we assess the feasibility of detecting human pancreatic cancer cells using a field effect transistor (FET)-based biosensor with an extended Au gate for medical application. Pancreatic cancer is one of the most fatal cancers, and is very difficult to diagnose in its early stages. Gemcitabine is an anticancer drug, and when used in chemotherapy it induces cell death. During apoptosis, the surface potential of the pancreatic cancer cells is changed by gemcitabine. In the present study, this change was detected using an FET-based biosensor. This biosensor was fabricated with an extended Au gate, whose surface is a sensing area for cancer cells. A null-balancing circuit was used in the measurement system, and the LabVIEW software platform allowed the immune-reaction at the Au gate to be detected as an output voltage. The cancer cells were incubated for one day; during this time, the cancer cells adhered to the Au extended gate surface. As gemcitabine was introduced to the cancer cells in vitro, changes in the output of the biosensor were monitored. Pancreatic cancer cells with a resistance to gemcitabine were used to verify that the change in the output of the biosensor was due only to the interaction between the cancer cells and the gemcitabine. We also investigated the relationship between the starting time of the reaction and the concentration of the anticancer drug.

AB - In this paper, we assess the feasibility of detecting human pancreatic cancer cells using a field effect transistor (FET)-based biosensor with an extended Au gate for medical application. Pancreatic cancer is one of the most fatal cancers, and is very difficult to diagnose in its early stages. Gemcitabine is an anticancer drug, and when used in chemotherapy it induces cell death. During apoptosis, the surface potential of the pancreatic cancer cells is changed by gemcitabine. In the present study, this change was detected using an FET-based biosensor. This biosensor was fabricated with an extended Au gate, whose surface is a sensing area for cancer cells. A null-balancing circuit was used in the measurement system, and the LabVIEW software platform allowed the immune-reaction at the Au gate to be detected as an output voltage. The cancer cells were incubated for one day; during this time, the cancer cells adhered to the Au extended gate surface. As gemcitabine was introduced to the cancer cells in vitro, changes in the output of the biosensor were monitored. Pancreatic cancer cells with a resistance to gemcitabine were used to verify that the change in the output of the biosensor was due only to the interaction between the cancer cells and the gemcitabine. We also investigated the relationship between the starting time of the reaction and the concentration of the anticancer drug.

UR - http://www.scopus.com/inward/record.url?scp=84861829840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861829840&partnerID=8YFLogxK

U2 - 10.4015/S1016237212500196

DO - 10.4015/S1016237212500196

M3 - Article

AN - SCOPUS:84861829840

VL - 24

SP - 131

EP - 137

JO - Biomedical Engineering - Applications, Basis and Communications

JF - Biomedical Engineering - Applications, Basis and Communications

SN - 1016-2372

IS - 2

ER -